Novartis’s Chief Medical Officer On All Things MS And The Science Of Operations
Shreeram Aradhye, Novartis’s Global Head, Medical Affairs, and Chief Medical Officer (Pharmaceuticals), outlines the company’s all-encompassing-approach for multiple sclerosis therapies. In a wide-ranging interview with Scrip, Aradhye also touches on the promise of gene therapy and how emerging technologies are helping shape medical innovation.
You may also be interested in...
Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.
Novartis’s Luxturna Deal Expands Gene Therapy Ambitions
By licensing Spark Therapeutics' Luxturna outside the US, Novartis is expanding its gene therapy ambitions into in vivo and non-oncological treatments.
What's Gilead Getting From Kite For Nearly $12bn?
The $180 per share that Gilead's paying for CAR-T maker Kite was deemed too high by some and just right by others, but the big biotech expects a lot from its new cell therapy platform.